Industry Overview

India silent heart attack market was valued at $188.6 million in 2025 and is projected to reach $433.7 million by 2035, growing at a CAGR of 8.7% from 2026 to 2035. Silent myocardial infarction represents a critical subset of cardiovascular diseases in which symptoms often go unnoticed, leading to delayed diagnosis and a higher risk of severe complications. The market encompasses a broad range of diagnostic technologies, including electrocardiogram (ECG) systems, cardiac biomarker testing, advanced imaging modalities, and wearable monitoring devices. It also includes treatment approaches such as pharmacological therapies and interventional procedures. The increasing prevalence of cardiovascular diseases in India—driven by rapid urbanization, sedentary lifestyles, and rising incidences of diabetes and hypertension—is a key factor fueling market growth. Additionally, growing awareness of preventive healthcare and the importance of early diagnosis is accelerating the adoption of advanced diagnostic solutions across hospitals, cardiology clinics, and diagnostic centers.

Recent technological advancements and product innovations are further strengthening the market landscape by enhancing both diagnostic and treatment capabilities. In October 2025, Medtronic launched its Avalus Ultra surgical aortic valve in India, offering next-generation valve replacement technology aimed at improving surgical outcomes, durability, and long-term patient management in aortic valve disease. Similarly, in May 2024, Abbott introduced its GLP Systems Track automation solution in India, designed to improve laboratory efficiency and significantly reduce turnaround time by minimizing manual processes. This system supports high-volume diagnostic testing and addresses the growing demand for laboratory services associated with chronic diseases. Such advancements contribute to the development of robust diagnostic infrastructure and improved interventional care, indirectly supporting the early detection and effective management of silent myocardial infarction. Collectively, these innovations are expanding access to advanced cardiac diagnostics and treatments, thereby driving overall market growth.

Market Dynamics

ECG Leads the Way in Early Detection of Silent Heart Attacks

Electrocardiogram (ECG) holds a dominant position in the diagnostic segment of the silent heart attack market. Its widespread availability across hospitals, clinics, and primary healthcare centers makes it highly accessible. ECG is a cost-effective diagnostic tool, enabling large-scale cardiac screening, especially in emerging economies like India. It serves as the first-line screening method for detecting cardiac abnormalities, including silent myocardial infarction. The ability to deliver quick and reliable results enhances its adoption in both emergency and routine care settings. Growing government initiatives to expand cardiac screening programs are further boosting ECG usage. As a result, ECG continues to play a critical role in early diagnosis and timely intervention in cardiovascular care.

Affordable Drug Access Driving Growth in Pharmacological Treatment Segment

Pharmacological treatment dominates the market due to its accessibility, affordability, and widespread use as the first line of management for cardiovascular conditions, including silent heart attacks. It plays a critical role in controlling risk factors such as hypertension, cholesterol, and thrombosis. In December 2024, the Government of India strengthened the National Programme for Prevention and Control of Non-Communicable Diseases (NP-NCD). The initiative focuses on expanding access to affordable cardiovascular medications across public healthcare systems. It includes the distribution of over 2,000 essential drugs under schemes like Pradhan Mantri Bhartiya Janaushadhi Pariyojana. This significantly improves treatment accessibility for patients with chronic diseases nationwide. Such efforts enhance pharmacological management and support the growth of the India silent heart attack market.

Market Segmentation

• Based on diagnostic, the market is segmented into electrocardiogram (ECG), cardiac biomarkers testing (troponin, CK-MB), cardiac imaging, and wearable & remote monitoring devices.
• Based on treatment type, the market is segmented into pharmacological treatment, interventional procedures, and lifestyle & preventive management.
• Based on end-user, the market is segmented into hospitals, cardiology clinics, diagnostic centers, and homecare settings.

Advanced Hospital Infrastructure Driving Cardiac Care Innovation in India

Hospitals dominate the end-user segment due to the presence of advanced diagnostic infrastructure, skilled cardiologists, and the ability to perform complex interventional procedures. They serve as primary centers for early diagnosis and treatment of silent myocardial infarction. The availability of imaging systems, ECG monitoring, and catheterization labs strengthens their leadership position. Such innovations enable hospitals to deliver more precise and effective interventional cardiac care. This advancement supports improved treatment pathways and contributes to the growth of the Indian silent heart attack market.

 Rising Adoption of Wearable & Remote Monitoring Devices in India

Wearable & remote monitoring devices are emerging as a rapidly growing diagnostic segment in India due to increasing awareness regarding preventive cardiac healthcare and the rising burden of undiagnosed cardiovascular diseases. Smartwatches, portable ECG monitors, and AI-enabled cardiac tracking devices are gaining popularity among urban and high-risk populations for continuous heart monitoring and early detection of silent cardiac abnormalities. The growing penetration of digital health platforms, smartphone connectivity, and telemedicine services is further supporting segment expansion. Government initiatives promoting digital healthcare infrastructure and remote patient monitoring are also encouraging adoption across semi-urban and rural areas. In addition, increasing investments by healthcare technology companies in affordable wearable cardiac solutions are improving accessibility. These technologies help in identifying irregular heart rhythms and asymptomatic cardiac events at an early stage, thereby supporting timely medical intervention. The rising preference for home-based monitoring and preventive healthcare is expected to strengthen the growth of this segment in the Indian silent heart attack market.

 Market Players Outlook

The major companies operating in the India silent heart attack market include Abbott Laboratories, Medtronic, Siemens Healthineers, Danaher, and Philips Healthcare, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisitions to expand their businesses and develop innovative products, maintaining their market positioning.

Recent Development

• In February 2026, OMRON Healthcare announced expansion of its AI-driven remote ECG diagnosis strategy in India through deeper collaboration with Indian health-tech firm Tricog Health. The company expanded pilot services for home-based cardiac monitoring and recovery management, targeting wider deployment across clinics and households in India during FY2026. This expansion supports early detection of silent cardiac events and remote cardiovascular risk monitoring.

• In July 2025, AliveCor launched the AI-powered Kardia 12L ECG system in India, specifically designed to detect acute myocardial infarction (heart attack), cardiac ischemia, and multiple arrhythmias using a handheld 12-lead ECG platform. The product received CDSCO approval and expanded AliveCor’s cardiac diagnostics portfolio in India, strengthening early and silent heart attack detection capabilities in hospitals and remote healthcare settings.

• In May 2024, OMRON Healthcare India partnered with AliveCor to strengthen AI-enabled ECG monitoring solutions in India. The collaboration focused on expanding access to personal ECG technology capable of detecting irregular heart rhythms and hidden cardiac abnormalities linked with silent heart attack risks. The partnership marked OMRON’s expansion into AI-driven cardiac diagnostics and remote heart monitoring in the Indian market.

The Report Covers

• Market value data analysis of 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Key companies operating in the India silent heart attack market
• Based on the availability of data, information related to new Protections and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.